Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Therapeutic
- Biotechnology
- Wound Care
- Orthopedic
- Diagnostic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 368489
License Grant
University grants a exclusive license under Licensed Subject Matter to manufacture, have manufactured, sell, offer for Sale, import and use Licensed Product and Licensed Process within the Licensed Territory within the Licensed Field.
License Property
TP508 Technology shall mean any and all subject matter claimed in Patent Rights; and peptides which bind to and/or stimulate a thrombin receptor, compositions which contain such peptides, methods of producing such peptides, detecting such peptides, and utilizing such peptides diagnostically and/or therapeutically, including, but not limited to, thrombin derived polypeptides, agonists, or antagonists of the proteolytically or non-proteolytically activated thrombin receptor or receptors or agonists and antagonists of other cellular effects activated by proteolytic or non-proteolytic thrombin interactions and which are made or developed by Carney or any University employee working under the supervision or direction of Carney.
Field of Use
Chrysalin, or TP508, is a 23-amino acid synthetic peptide representing a receptor-binding domain of the human thrombin molecule, a naturally occurring molecule in the body responsible for both blood clotting and initiating many of the cellular events responsible for tissue repair in bone and cartilage. By mimicking specific attributes of the thrombin molecule, Chrysalin stimulates the body’s natural healing processes, resulting in accelerated tissue repair.
Licensee is a biopharmaceutical company developing synthetic peptide compounds targeted at tissue repair and regeneration.
IPSCIO Record ID: 28032
License Grant
Board hereby grants and agrees to grant to Licensee a royalty-bearing, exclusive license under Licensed Subject Matter to manufacture, have manufactured, sell, offer for Sale, import and use Licensed Product and Licensed Process within the Licensed Territory within the Licensed Field; provided, however.
License Property
TP508 Technology shall mean (i) any and all subject matter claimed in Patent Rights; and (ii) peptides which bind to and/or stimulate a thrombin receptor, compositions which contain such peptides, methods of producing such peptides, detecting such peptides, and utilizing such peptides diagnostically and/or therapeutically, including, but not limited to, thrombin derived polypeptides, agonists or antagonists of the proteolytically or non-proteolytically activated thrombin receptor or receptors or agonists and antagonists of other cellular effects activated by proteolytic or non-proteolytic thrombin interactions and which are made or developed by Carney or any University employee working under the supervision or direction of Carney.
TP508 is a 23-amino acid synthetic peptide representing a receptor-binding domain of the human thrombin molecule, a naturally occurring molecule in the body responsible for both blood clotting and initiating many of the cellular events responsible for tissue repair in bone and cartilage. A single topical application of TP508 stimulates revascularization and healing of acute incisional and excisional wounds in normal, healthy rat skin.
Field of Use
Licensed Field shall mean all fields of use.
IPSCIO Record ID: 160766
License Grant
Licensor hereby grants to Licensee a series of options to acquire exclusive United States and worldwide licenses, as set forth below, to make or have made, use, sell and sublicense Licensed Products under the Technology Rights for Orthopaedic Applications of the type described. Each such license shall run for the lives of all Patents and other patents owned by or licensed to Licensor, and related to any Licensed Product, which are appropriate for the territory licensed.
License Property
Licensed Products means devices or materials including but not limited to TP508 and related peptides, all products using any of such materials, Licensor Technology or any of the Technology Rights, and all other products which, in the course of their manufacture, use, or sale would, in the absence of this license, infringe one or more claims of any of the Patent Rights which have not been finally adjudicated to be invalid by a court of competent jurisdiction.
Licensor Technology means the core technologies related to the Patents, including the TP508 Peptide.
Licensor Product means TP508 or any related peptides, or any other materials or products manufactured by or for Licensor and sold to Licensee for research, treatment of patients or resale.
Patents means U.S. patents Number 5,352,664 and 5,500,412, all related foreign patents, including patents issued in Europe, Canada and Japan, and any divisional, continuation, and continuation-in-part applications and patents based thereon, any reissues or extensions thereof, and any corresponding or additional United States and foreign patent applications.
Field of Use
This agreement pertains to the medical industry relating to Orthopaedic Applications that shall include, and be limited to, the use of the Technology Rights in connection with Treatment of fractures, osteoarthritis or osteoporosis, treatment of damage to meniscus, ligament, cartilage or tendon, preparation or application of segmental bone filling, coating or preparation of bone or joint implants, and spinal fusion (bone related).
IPSCIO Record ID: 3187
License Grant
As part of our purchase of Chrysalis Biotechnology, Inc. on August 5, 2004, the License Agreements between CBI and OrthoLogic for the development, use, and marketing of the therapeutic products utilizing Chrysalin (TP508) were replaced by a direct License Agreement between the Licensee and the University of Texas.
Subsequently, Licensee entered into an Agreement whereby the University of Texas assigned to the Licensee certain patents previously exclusively Licensed to the Licensee.
License Property
Under this Agreement, the Licensee must pay the University of Texas royalties and subLicense fees and pay various other fees in connection with filing and maintaining Chrysalin-related patents.
Chrysalin has been patented in the United States and in some other countries for a number of methods of use, including cardiovascular indications.
A composition of matter patent covering European countries expired in 2007 and the corresponding United States patent expired in 2011. Our other patents for Chrysalin expire between 2021 and 2024.
On January 20, 2012, the Licensee announced the intent to cease all activities related to the development of Chrysalin and to return the patent and other intellectual property we own related to Chrysalin to the original licensor.
Field of Use
Chrysalin (TP508), a novel synthetic 23-amino acid peptide, is believed to produce angiogenic and other tissue repair effects in part by 1) activating or upregulating endothelial nitric oxide synthase (eNOS); 2) cytokine modulation resulting in an anti-inflammatory effect; 3) inhibiting apoptosis (programmed cell death); and 4) modulating angiogenic factors. It may have therapeutic value in diseases associated with endothelial dysfunction.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
